C4 Therapeutics, Inc. (CCCC)
3.10
+0.15
(+5.08%)
USD |
NASDAQ |
Nov 06, 16:00
3.09
-0.01
(-0.32%)
After-Hours: 20:00
C4 Therapeutics Enterprise Value : 256.91M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 256.91M |
| November 05, 2026 | 237.21M |
| November 04, 2026 | 259.53M |
| November 03, 2026 | 271.35M |
| November 02, 2026 | 271.35M |
| October 30, 2026 | 292.36M |
| October 29, 2026 | 283.17M |
| October 28, 2026 | 295.64M |
| October 27, 2026 | 271.35M |
| October 26, 2026 | 241.15M |
| October 23, 2026 | 251.65M |
| October 22, 2026 | 267.41M |
| October 21, 2026 | 266.10M |
| October 20, 2026 | 264.79M |
| October 19, 2026 | 229.33M |
| October 16, 2026 | 212.92M |
| October 15, 2026 | 214.89M |
| October 14, 2026 | 192.56M |
| October 13, 2026 | 214.89M |
| October 12, 2026 | 251.65M |
| October 09, 2026 | 264.79M |
| October 08, 2026 | 224.08M |
| October 07, 2026 | 220.14M |
| October 06, 2026 | 228.02M |
| October 05, 2026 | 242.46M |
| Date | Value |
|---|---|
| October 02, 2026 | 237.21M |
| October 01, 2026 | 262.16M |
| September 30, 2026 | 287.11M |
| September 29, 2026 | 187.89M |
| September 28, 2026 | 186.05M |
| September 25, 2026 | 169.45M |
| September 24, 2026 | 175.60M |
| September 23, 2026 | 181.74M |
| September 22, 2026 | 210.01M |
| September 21, 2026 | 208.78M |
| September 18, 2026 | 219.85M |
| September 17, 2026 | 222.92M |
| September 16, 2026 | 227.22M |
| September 15, 2026 | 224.76M |
| September 14, 2026 | 224.76M |
| September 11, 2026 | 234.59M |
| September 10, 2026 | 221.07M |
| September 09, 2026 | 225.99M |
| September 08, 2026 | 239.51M |
| September 04, 2026 | 265.32M |
| September 03, 2026 | 262.86M |
| September 02, 2026 | 269.01M |
| September 01, 2026 | 278.84M |
| August 31, 2026 | 259.18M |
| August 28, 2026 | 276.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.348B |
| Kymera Therapeutics, Inc. | 10.35B |
| NKGen Biotech, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 7.983B |
| Oncolytics Biotech, Inc. | 51.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.84M |
| Revenue (Quarterly) | 8.468M |
| Total Expenses (Quarterly) | 30.31M |
| EPS Diluted (Quarterly) | -0.1605 |
| Gross Profit Margin (Quarterly) | 78.90% |
| Profit Margin (Quarterly) | -257.9% |
| Earnings Yield | -23.10% |
| Normalized Earnings Yield | -23.10 |